{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T09:33:24Z","timestamp":1790847204858,"version":"4.1.0"},"reference-count":35,"publisher":"Society of Nuclear Medicine","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Nucl Med"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.2967\/jnumed.122.265242","type":"journal-article","created":{"date-parts":[[2023,3,30]],"date-time":"2023-03-30T15:20:18Z","timestamp":1680189618000},"page":"1024-1029","source":"Crossref","is-referenced-by-count":53,"title":["PSMA PET Tumor\u2013to\u2013Salivary Gland Ratio to Predict Response to [\n                    <sup>177<\/sup>\n                    Lu]PSMA Radioligand Therapy: An International Multicenter Retrospective Study"],"prefix":"10.2967","volume":"64","author":[{"given":"Masatoshi","family":"Hotta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrei","family":"Gafita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vishnu","family":"Murthy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias R.","family":"Benz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ida","family":"Sonni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene A.","family":"Burger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Eiber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louise","family":"Emmett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Farolfi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang P.","family":"Fendler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel M.","family":"Weber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael S.","family":"Hofman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas A.","family":"Hope","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clemens","family":"Kratochwil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes","family":"Czernin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremie","family":"Calais","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1602","published-online":{"date-parts":[[2023,3,30]]},"reference":[{"key":"2023063006250740000_64.7.1024.1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2107322"},{"key":"2023063006250740000_64.7.1024.2","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/S0140-6736(21)00237-3","article-title":"[177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial","volume":"397","author":"Hofman","year":"2021","journal-title":"Lancet."},{"key":"2023063006250740000_64.7.1024.3","doi-asserted-by":"crossref","first-page":"7812","DOI":"10.7150\/thno.47251","article-title":"Analysis of PSMA expression and outcome in patients with advanced prostate cancer receiving 177Lu-PSMA-617 radioligand therapy","volume":"10","author":"Seifert","year":"2020","journal-title":"Theranostics."},{"key":"2023063006250740000_64.7.1024.4","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1016\/S1470-2045(21)00274-6","article-title":"Nomograms to predict outcomes after 177Lu-PSMA therapy in men with metastatic castration-resistant prostate cancer: an international, multicentre, retrospective study","volume":"22","author":"Gafita","year":"2021","journal-title":"Lancet Oncol."},{"key":"2023063006250740000_64.7.1024.5","doi-asserted-by":"crossref","first-page":"2322","DOI":"10.1007\/s00259-020-04723-z","article-title":"Prognostic biomarkers in men with metastatic castration-resistant prostate cancer receiving [177Lu]-PSMA-617","volume":"47","author":"Ferdinandus","year":"2020","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2023063006250740000_64.7.1024.6","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1016\/S1470-2045(22)00605-2","article-title":"PSMA and FDG-PET as predictive and prognostic biomarkers in patients given [177Lu]Lu-PSMA-617 versus cabazitaxel for metastatic castration-resistant prostate cancer (TheraP): a biomarker analysis from a randomised, open-label, phase 2 trial","volume":"23","author":"Buteau","year":"2022","journal-title":"Lancet Oncol."},{"key":"2023063006250740000_64.7.1024.7","doi-asserted-by":"crossref","first-page":"5002","DOI":"10.1200\/JCO.2022.40.16_suppl.5002","article-title":"[68Ga]Ga-PSMA-11 PET baseline imaging as a prognostic tool for clinical outcomes to [177Lu]Lu-PSMA-617 in patients with mCRPC: a VISION substudy [abstract]","volume":"40","author":"Kuo","year":"2022","journal-title":"J Clin Oncol."},{"key":"2023063006250740000_64.7.1024.8","unstructured":"Highlights of prescribing information. Pluvicto\u00ae (lutetium Lu 177 vipivotide tetraxetan) injection, for intravenous use. Food and Drug Administration website. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/215833s000lbl.pdf. Revised March 2022. Accessed March 15, 2023."},{"key":"2023063006250740000_64.7.1024.9","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30198-0"},{"key":"2023063006250740000_64.7.1024.10","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.121.261982"},{"key":"2023063006250740000_64.7.1024.11","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.121.262543"},{"key":"2023063006250740000_64.7.1024.12","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1002\/pros.24104","article-title":"Imaging expression of prostate-specific membrane antigen and response to PSMA-targeted \u03b2-emitting radionuclide therapies in metastatic castration-resistant prostate cancer","volume":"81","author":"Vlachostergios","year":"2021","journal-title":"Prostate."},{"key":"2023063006250740000_64.7.1024.13","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.119.231431"},{"key":"2023063006250740000_64.7.1024.14","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.120.241588"},{"key":"2023063006250740000_64.7.1024.15","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1200\/JCO.2022.40.6_suppl.TPS211","article-title":"PSMAfore: a phase 3 study to compare 177Lu-PSMA-617 treatment with a change in androgen receptor pathway inhibitor in taxane-na\u00efve patients with metastatic castration-resistant prostate cancer [abstract]","volume":"40","author":"Sartor","year":"2022","journal-title":"J Clin Oncol."},{"key":"2023063006250740000_64.7.1024.16","doi-asserted-by":"crossref","first-page":"5087","DOI":"10.1200\/JCO.2021.39.15_suppl.TPS5087","article-title":"Study evaluating metastatic castrate resistant prostate cancer (mCRPC) treatment using 177Lu-PNT2002 PSMA therapy after second-line hormonal treatment (SPLASH) [abstract]","volume":"39","author":"Chi","year":"2021","journal-title":"J Clin Oncol."},{"key":"2023063006250740000_64.7.1024.17","doi-asserted-by":"crossref","first-page":"5596","DOI":"10.1200\/JCO.2020.38.15_suppl.TPS5596","article-title":"A multicenter, randomized, controlled phase II study: efficacy and safety of PSMA-targeted radioligand therapy I-131-1095 (1095) plus enzalutamide (enza) in 18F-DCFPyL PSMA scan avid, metastatic castration-resistant prostate cancer (mCRPC) patients post-abiraterone (abi) progression (ARROW) [abstract]","volume":"38","author":"Yu","year":"2020","journal-title":"J Clin Oncol."},{"key":"2023063006250740000_64.7.1024.18","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.121.263638"},{"key":"2023063006250740000_64.7.1024.19","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.121.263441"},{"key":"2023063006250740000_64.7.1024.20","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.121.261906"},{"key":"2023063006250740000_64.7.1024.21","doi-asserted-by":"publisher","DOI":"10.1186\/s13550-014-0063-1"},{"key":"2023063006250740000_64.7.1024.22","doi-asserted-by":"crossref","first-page":"5028","DOI":"10.1200\/JCO.2019.37.15_suppl.5028","article-title":"RESIST-PC phase 2 trial: 177Lu-PSMA-617 radionuclide therapy for metastatic castrate-resistant prostate cancer [abstract]","volume":"37","author":"Calais","year":"2019","journal-title":"J Clin Oncol."},{"key":"2023063006250740000_64.7.1024.23","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.115.171397"},{"key":"2023063006250740000_64.7.1024.24","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.118.224055"},{"key":"2023063006250740000_64.7.1024.25","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.64.2702"},{"key":"2023063006250740000_64.7.1024.26","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-0587"},{"key":"2023063006250740000_64.7.1024.27","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1007\/s00259-020-05160-8","article-title":"Prognostic implications of dual tracer PET\/CT: PSMA ligand and [18F]FDG PET\/CT in patients undergoing [177Lu]PSMA radioligand therapy","volume":"48","author":"Michalski","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2023063006250740000_64.7.1024.28","doi-asserted-by":"crossref","first-page":"4134","DOI":"10.3390\/cancers13164134","article-title":"Value of combined PET imaging with [18F]FDG and [68Ga]Ga-PSMA-11 in mCRPC patients with worsening disease during [177Lu]Lu-PSMA-617 RLT","volume":"13","author":"Khreish","year":"2021","journal-title":"Cancers (Basel)."},{"key":"2023063006250740000_64.7.1024.29","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.108.057182"},{"key":"2023063006250740000_64.7.1024.30","doi-asserted-by":"crossref","unstructured":"Klyuzhin IS Chauss\u00e9 G Bloise I Ferres JL Uribe C Rahmim A . PSMA-Hornet: fully-automated, multi-target segmentation of healthy organs in PSMA PET\/CT images. medRxiv website. https:\/\/www.medrxiv.org\/content\/10.1101\/2022.02.02.22270344v1. Published February 5, 2022. Accessed March 15, 2023.","DOI":"10.1101\/2022.02.02.22270344"},{"key":"2023063006250740000_64.7.1024.31","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.120.242057"},{"key":"2023063006250740000_64.7.1024.32","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.120.261863"},{"key":"2023063006250740000_64.7.1024.33","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1007\/s00259-021-05497-8","article-title":"Analytical performance of aPROMISE: automated anatomic contextualization, detection, and quantification of [18F]DCFPyL (PSMA) imaging for standardized reporting","volume":"49","author":"Johnsson","year":"2022","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2023063006250740000_64.7.1024.34","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s40644-019-0211-y","article-title":"Intra-individual comparison of 68Ga-PSMA-11 and 18F-DCFPyL normal-organ biodistribution","volume":"19","author":"Ferreira","year":"2019","journal-title":"Cancer Imaging."},{"key":"2023063006250740000_64.7.1024.35","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.120.243295"}],"container-title":["Journal of Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.2967\/jnumed.122.265242","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,30]],"date-time":"2023-06-30T09:27:01Z","timestamp":1688117221000},"score":1,"resource":{"primary":{"URL":"http:\/\/jnm.snmjournals.org\/lookup\/doi\/10.2967\/jnumed.122.265242"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,30]]},"references-count":35,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2023,6,30]]},"published-print":{"date-parts":[[2023,7]]}},"alternative-id":["10.2967\/jnumed.122.265242"],"URL":"https:\/\/doi.org\/10.2967\/jnumed.122.265242","relation":{},"ISSN":["0161-5505","2159-662X"],"issn-type":[{"value":"0161-5505","type":"print"},{"value":"2159-662X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,30]]}}}